Project Grant R21CA314232
Award Date 5/7/26
Completion Date 4/30/28
Dollars Obligated $396K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Austin, TX 78712, USA
Similar Awards
- Federal Project Grant Award Summary The University of Texas MD Anderson Cancer Center received a $370,173 Project Grant from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393), awarded September 9, 2025, with completion targeted for August 31, 2030. This award funds research to develop and validate advanced methodologies for measuring and characterizing genetic interactions in cancer cells, with particular emphasis on identifying synthetic...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $402,011 Project Grant to The University of Texas Southwestern Medical Center under the Cancer Biology Research program (CFDA 93.396) effective May 1, 2026, through April 30, 2031. This five-year research initiative investigates the molecular mechanisms by which the KEAP1-NRF2 redox-sensing pathway regulates CD8 T cell adaptation to chronic antigen receptor signaling in cancer and chronic infection contexts. The research...
- Federal Grant Award Summary The University of Texas Southwestern Medical Center received a $639,514 Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) effective June 1, 2026, through May 31, 2031. This five-year research initiative funds mechanistic characterization studies of benzothiazepinone compounds, specifically MM17, which inhibit NVL (a critical AAA+ adenosine triphosphatase enzyme involved in ribosomal subunit...
- Federal Grant Award Summary The National Cancer Institute awarded a $404,972 Project Grant to The University of Texas Health Science Center at San Antonio under the Cancer Biology Research program (CFDA 93.396) for a two-year project period beginning August 1, 2025 and concluding July 31, 2027. This award supports fundamental research investigating ribosomal ribonucleic acid (rRNA) modification, ribosome composition, and specialized translation mechanisms in glioblastoma, the most common and...
- Federal Project Grant Award Summary Award Details: The National Cancer Institute (NCI), under the Cancer Research Manpower program (CFDA 93.398), awarded $150,104 to The University of Texas MD Anderson Cancer Center on December 18, 2025, with a completion date of June 2, 2028. Products and Services: This project grant supports the development of computational tools and analytical approaches to map the evolutionary trajectories of complex genome rearrangements in cancer. The award funds two...
- Federal Project Grant Award Summary The National Cancer Institute awarded a Project Grant totaling $194,914 under the Cancer Research Manpower program (CFDA 93.398) on September 15, 2025, to support cancer research training and investigator development. This award funds research led by Dr. Xu examining how structural variants (SVs) contribute to oncogene activation in cancer through genome engineering and single-cell sequencing approaches. The project runs through August 31, 2028, and will be...
- Federal Grant Award Summary The National Cancer Institute awarded the University of Texas at Austin a $2.59 million Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective August 1, 2025, through July 31, 2029. The award supports research to develop a novel cancer immunotherapy approach targeting immune-excluded or "cold" tumors that typically demonstrate poor response to immune checkpoint therapy. The project focuses on demonstrating that degradation of...
- Federal Grant Award Summary The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center a $420,400 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective August 1, 2025, through July 31, 2027. This award supports exploratory studies investigating cellular resistance mechanisms to second-generation MTA-cooperative PRMT5 inhibitors (MTA:PRMT5I) in MTAP-loss tumors. The research addresses a critical clinical challenge whereby 40-60% of patients...
- Federal Project Grant Award Summary The National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) awarded a $164,000 Project Grant to The University of Texas MD Anderson Cancer Center, effective September 1, 2025, through August 31, 2027. This award supports research investigating the clonal determinants of platinum/PARP inhibitor (PARPi) cross-resistance in high-grade serous ovarian cancer (HGSOC). The research utilizes a novel somatic mosaic genetically-engineered mouse model...
- Federal Grant Award Summary The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center a $498,565 Project Grant on September 8, 2025, under the Cancer Cause and Prevention Research program (CFDA 93.393) to develop a Globally Accessible and Pragmatic Predictive Signature (GAPPS) for locally advanced cervical cancer. The project, with a completion date of July 31, 2029, addresses the critical need for risk stratification biomarkers to personalize complex treatment...